Targets › SLC30A1
4 programs from 4 companies in 4 trials: 3 Phase 2, 1 Phase 4; Metabolic and endocrine, Genitourinary, Other; next expected readout Dec 2026.
Zinc ion:proton antiporter that could function at the plasma membrane mediating zinc efflux from cells against its electrochemical gradient protecting them from intracellular zinc accumulation and toxicity. Alternatively, could prevent the transport to the plasma membrane of CACNB2, the L-type calcium channels regulatory subunit, through a yet to be defined mechanism. (UniProt, Q9Y6M5)
Open in Phaseline: the race on SLC30A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Augusta University | 3 mg/day Zinc Supplementation Zinc supplementation (higher dose) | SLC30A1 | Phase 4 | Extreme Prematurity,Extremely Low Birthweight | May 2027 |
| Endeavor Health | Zinc Citrate Oral Capsule with phytase Zinc supplementation with phytase co-factor to enhance zinc bioavailability | SLC30A1 | Phase 2 | Overactive Bladder (OAB) | Dec 2026 |
| Quaid-e-Azam Medical College | Zinc sulfate Zinc supplementation - cofactor for bilirubin metabolism and antioxidant support | SLC30A1 | Phase 2 | Indirect Hyperbilirubinemia | – |
| Universitas Indonesia | Zinc, Chromium, Vitamin C, and Copper Supplementation Combination mineral and vitamin supplement: zinc enhances insulin signaling and glucose me | SLC30A1, CREBBP, SLC31A1 | Phase 2 | PreDiabetes | – |
Overactive Bladder (OAB) (1) Indirect Hyperbilirubinemia (1) PreDiabetes (1) Extreme Prematurity,Extremely Low Birthweight (1)
small molecule (3)
Endeavor Health (1) Quaid-e-Azam Medical College (1) Universitas Indonesia (1) Augusta University (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.